Basic Sinequan Information

• INN (International Nonproprietary Name): Doxepin
• Brand Names Available In United Kingdom: Sinequan (listed for USA, UK, export) and generics; Silenor is marketed in the USA for insomnia but low‑dose doxepin is used off‑label in UK practice.
• ATC Code: N06AA12
• Forms & Dosages: Capsules 10 mg, 25 mg, 50 mg, 75 mg, 100 mg; oral solution 10 mg/mL; Silenor tablets 3 mg and 6 mg (for insomnia).
• Manufacturers In United Kingdom: Supplied widely as generics by manufacturers such as Mylan and Teva and various local generics manufacturers.
• Registration Status In United Kingdom: Registered as prescription only (Rx); generic approvals are prevalent.
• OTC / Rx Classification: Prescription only (Rx).

Key Findings From Recent Trials (2022–2025)

What Clinicians And Patients Ask: Has new research changed how we use doxepin?

High‑quality randomised controlled trial activity focused specifically on doxepin between 2022 and 2025 is limited.

The clearest practice‑changing evidence in that period concerns low‑dose doxepin used for insomnia, particularly Silenor preparations.

Observational datasets and re‑analyses have revisited older tricyclics in treatment‑resistant depression rather than producing many new doxepin RCTs.

Major 2022–2025 Studies

Most contemporary papers are meta‑analyses or cohort re‑evaluations rather than fresh, large doxepin trials.

Low‑dose doxepin insomnia trials and Silenor data remain the most robust prospective results in the window 2022–2025.

Observational cohorts looked again at tricyclic efficacy in resistant depression and included doxepin in pooled analyses.

Main Outcomes

Across studies, antidepressant efficacy of doxepin aligns with classic tricyclic response rates seen historically.

Low‑dose nocturnal doxepin (3–6 mg) shows consistent improvements in sleep continuity and maintenance with fewer systemic effects than standard antidepressant doses.

Systematic reviews continue to show that while doxepin is effective, its side‑effect profile differs from SSRIs because of anticholinergic and sedative effects.

Safety Observations

Recent pharmacovigilance confirms known risks, including anticholinergic effects and orthostatic hypotension, particularly at antidepressant doses.

Cardiac conduction abnormalities remain a concern at higher doses, supporting ECG monitoring for at‑risk patients in UK practice.

Regulators and clinicians continue to advise careful use in the elderly because of fall risk and cognitive effects from anticholinergic burden.

Clinical Mechanism Of Action

Patients Often Ask: How Does Doxepin Help Mood And Sleep?

Layman’s Explanation

Doxepin is a tricyclic antidepressant that lifts mood at higher doses and helps sleep at low doses.

The drug blocks the reuptake of certain brain chemicals and strongly blocks histamine receptors, which causes sedation.

That strong antihistamine effect is why low‑dose doxepin is useful for sleep maintenance without the full antidepressant side‑effect load.

Scientific Breakdown

Doxepin inhibits reuptake of norepinephrine and serotonin to varying degrees, contributing to its antidepressant properties.

The drug has high affinity for H1 histamine receptors, and H1 blockade underpins marked sedation exploited in low‑dose insomnia treatment such as Silenor 3–6 mg tablets.

Anticholinergic (muscarinic) blockade causes dry mouth, constipation and blurred vision, while α1‑adrenergic blockade explains orthostatic hypotension and dizziness.

Hepatic metabolism via cytochrome P450 pathways determines plasma levels and explains why dose adjustments are needed for hepatic impairment and why interacting drugs matter.

Pharmacokinetic Considerations

Formulation affects dosing flexibility; capsules are commonly available in 10–100 mg strengths for antidepressant titration.

An oral solution of 10 mg/mL exists in some markets and supports careful titration when required.

Silenor tablets at 3 mg and 6 mg are manufactured specifically for low‑dose hypnotic use and allow plasma exposures that favour H1 blockade over systemic anticholinergic effects.

Therapeutic onset for mood symptoms may take one to three weeks, while sedative effects occur rapidly after a single nocturnal dose.

Scope Of Approved & Off‑Label Use

People Want To Know: What Is Doxepin Licensed For In The UK And What Do Clinicians Use It For Off‑Label?

United Kingdom Approvals

In the UK, doxepin is a prescription‑only tricyclic antidepressant used primarily for depression and anxiety where a TCA is indicated.

Brand Sinequan appears in export and UK listings and generic doxepin is widely available in community and hospital settings.

Silenor is a US product for insomnia, and although Silenor itself is not a widespread UK brand, clinicians commonly use low‑dose doxepin off‑label for sleep disturbances.

Notable Off‑Label Trends

UK prescribers often use low‑dose nightly doxepin (typically 3–10 mg) for chronic insomnia when non‑pharmacological options have failed.

This approach exploits antihistaminic sedation while aiming to minimise anticholinergic burden associated with higher antidepressant doses.

For depression, doxepin is increasingly reserved for second‑line use when SSRIs are ineffective or not tolerated, reflecting modern prescribing trends.

Availability of multiple formulations—capsules, solution and Silenor tablets—supports flexible dosing choices in specialised settings.

Dosage Strategy

A Common Question: How Should Doxepin Be Dosed For Different Conditions?

General Dosing

Start low and titrate slowly while balancing antidepressant benefit against anticholinergic and cardiac risks.

Lower starting doses are advised in the elderly and in patients with hepatic or renal impairment.

Doxepin is generally not recommended for children under 12, and use in adolescents should be cautious and specialist‑led.

Condition‑Specific Dosing

Depression and Anxiety: The standard adult starting dose recorded in product information is 75 mg per day, given divided or at night.

The usual therapeutic range is 75–150 mg per day, with specialist services sometimes using up to 300 mg per day for treatment‑resistant cases.

Titrate weekly with clinical review and consider baseline ECG where there is cardiac risk or in older patients.

Insomnia: For sleep maintenance, Silenor dosing is 3–6 mg at bedtime, which exploits H1 antagonism with minimal systemic anticholinergic effects.

Special Populations: In elderly patients consider initiating antidepressant dosing at 25–50 mg per day and monitor for sedation, orthostatic hypotension and cognitive change.

In hepatic or severe renal impairment start at a lower dose and increase cautiously while monitoring clinical response and side effects.

Safety Protocols

Patients And Clinicians Ask: What Are The Big Safety Concerns With Doxepin?

Contraindications

Absolute contraindications are hypersensitivity to doxepin or other tricyclic antidepressants, narrow‑angle glaucoma, urinary retention, and MAOI use within the previous 14 days.

Use during pregnancy and lactation requires specialist input and should be limited to situations where benefit outweighs risk.

Relative contraindications include elderly frailty, severe hepatic or renal impairment, cardiac conduction disorders and a history of suicidality.

Adverse Effects

Common side effects include drowsiness, dry mouth, dizziness, blurred vision, constipation, urinary retention, weight gain and orthostatic hypotension.

Serious events such as cardiac arrhythmias and seizures are less frequent but require urgent medical attention when suspected.

Elderly patients are at higher risk of falls and confusion because of sedative and anticholinergic effects, so monitoring and dose reduction are important.

Overdose can cause severe drowsiness, cardiac arrhythmias or seizures and mandates immediate emergency care.

In UK practice, perform a baseline medication review, consider ECG if cardiac history or elderly, and document regular blood pressure and weight checks during follow‑up.

Interaction Mapping

What Drugs And Foods Should Be Avoided With Doxepin?

Food Interactions

Alcohol potentiates doxepin’s sedative effects and should be avoided while taking the medicine.

Other central nervous system depressants will also increase sedation and risk of falls.

Drug Combinations To Avoid

MAOIs within 14 days are an absolute contraindication due to risk of severe and potentially life‑threatening reactions.

Co‑prescription with other QT‑prolonging medicines increases cardiac risk and should be avoided or monitored closely.

Potent CYP inhibitors, especially inhibitors of CYP2D6 and CYP2C19, can raise doxepin plasma levels and increase toxicity risk; dose adjustments or alternative agents should be considered.

Concurrent serotonergic agents raise the risk of serotonin syndrome, and careful cross‑tapering protocols are needed when switching between classes.

In older patients avoid accumulating anticholinergic burden by reviewing co‑medications such as opioids or antimuscarinic bladder drugs.

Patient Experience Analysis

What Do Real Patients Say About Doxepin?

Survey Data

Patient surveys and observational cohorts report useful sleep improvement and antidepressant response for many users, but tolerability trade‑offs are common.

Daytime sedation, dry mouth and weight gain are among the most frequently reported complaints.

Clinical audits in UK practice show many patients experience quicker sleep onset and better sleep maintenance with low‑dose nocturnal doxepin compared with some hypnotics, though morning sedation varies.

Forum Trends

Online forums commonly contain two themes: successful sleep restoration at low Silenor‑equivalent doses and concern about anticholinergic effects and withdrawal after abrupt cessation.

Many patients report switching to generic doxepin formulations such as Sinequan equivalents with similar subjective effects.

Clinicians should set expectations carefully and advise gradual tapering to reduce the chance of rebound insomnia or discontinuation symptoms.

Distribution & Pricing Landscape

How Widely Available Is Doxepin And What Do Patients Pay?

Doxepin is widely available as generics supplied by manufacturers such as Mylan and Teva and by various local producers.

Brand variations exist by region with Sinequan listed for USA, UK and export, Silenor in the USA, Quitaxon in Spain and Doquel in Australia.

Common packaging includes capsules 10–100 mg, an oral solution 10 mg/mL and Silenor tablets 3 mg and 6 mg.

The UK market is dominated by generic formulations dispensed through community pharmacies and hospital trusts, with cost‑effective generic switching common in NHS primary care.

Pricing varies by pack size and supplier and is influenced by NHS procurement contracts and supplier availability.

For e‑commerce searches, patients often look for terms like “doxepin capsules”, “Sinequan 25 mg price” and “Silenor 3 mg tablets insomnia”.

In our online pharmacy, sinequan is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.

Alternative Options

Patients Ask: What Alternatives Exist If Doxepin Isn't Suitable?

Comparison Table

Compared With Other TCAs Such As Amitriptyline, Nortriptyline And Imipramine, doxepin Has Similar Antidepressant Efficacy But Different Tolerability.

Compared With SSRIs Such As Sertraline Or Fluoxetine, SSRIs Offer A More Favourable Side‑Effect Profile For First‑Line Depression Treatment.

Pros And Cons

Pros: Doxepin is an effective tricyclic antidepressant with potent H1 antagonism useful for insomnia at low doses and multiple generic formulations exist.

Cons: Pronounced anticholinergic effects, orthostatic hypotension and potential cardiac conduction effects at higher doses; increased fall risk in older adults.

Clinical Positioning: Reserve doxepin for patients who need sedative antidepressant effects, for those intolerant of SSRIs, or for targeted low‑dose hypnotic therapy.

Regulatory Status

How Is Doxepin Regulated Globally And In The UK?

Global Approvals Snapshot

Sinequan is discontinued in the USA as a brand but generics remain approved and widely dispensed.

In the EU and major markets multiple generics hold marketing authorisation and doxepin is prescription only.

Regional brand names include Sinequan (USA/UK/export), Silenor (USA for insomnia), Quitaxon (Spain) and Doquel (Australia).

UK Specifics & Prescribing Controls

Doxepin is prescription only in the UK and generic approvals are prevalent across suppliers such as Mylan and Teva.

Prescribers should follow MHRA guidance on contraindications, avoid MAOI co‑administration and report adverse events as per routine pharmacovigilance rules.

Consolidated FAQ

Quick Answers For Clinicians And Patients.

Is Doxepin Available In The UK?

Yes, generics and brand listings such as Sinequan appear in UK listings and doxepin is available as a prescription medication.

What Are The Typical Doses?

For depression, typical starting dose is 75 mg/day with a usual range of 75–150 mg/day and specialist doses up to 300 mg/day.

For insomnia, Silenor dosing is 3–6 mg at bedtime.

Elderly patients should start at lower doses such as 25–50 mg/day for antidepressant use.

What Are The Major Safety Points?

Avoid use with MAOIs within the previous 14 days and in patients with narrow‑angle glaucoma or urinary retention.

Monitor for anticholinergic effects, orthostatic hypotension and cardiac conduction problems, and consider ECG where appropriate.

What If A Dose Is Missed Or Overdose Occurs?

If a dose is missed take it as soon as remembered unless it is close to the next dose and do not double the dose to catch up.

Overdose requires immediate medical attention for severe drowsiness, cardiac symptoms or seizures.

Visual Guide

Which Visuals Help Clinicians Make Safer Decisions?

Diagrams And Infographics To Include

Recommended visuals include a dosing flowchart showing start, titration and monitoring checkpoints with elderly and hepatic impairment flags.

A mechanism diagram that contrasts monoamine reuptake blockade with H1/histamine and muscarinic receptor effects helps explain low‑dose versus high‑dose outcomes.

A side‑effect risk matrix plotting age, comorbidity and interacting drugs against monitoring frequency is very helpful in primary care.

A switching algorithm that shows cross‑tapering and the 14‑day washout from MAOIs supports safe class changes.

How Visuals Support Clinical Decisions

Visual aids distil trial, observational and product information into actionable steps for UK prescribers and pharmacists.

Include packaging images for capsules 10–100 mg and Silenor 3 mg/6 mg tablets to prevent dispensing errors and to aid patient education.

Storage & Transport

How Should Pharmacies And Patients Store Doxepin?

Best Practices For Pharmacies & Patients

Store doxepin formulations at room temperature, ideally between 15–30°C, and protect them from moisture and excessive heat.

Transport in original packaging to preserve labelling and traceability and to avoid contamination.

Keep blister packs or bottles sealed until dispensing and check expiry dates carefully on multi‑strength packs.

Advise patients to store medicines out of reach of children and to return unused medication to the pharmacy for safe disposal.

Regulatory/Packaging Notes

Pharmacies should segregate high‑risk medicines to reduce dispensing errors and maintain ambient storage in line with supplier guidance.

Be aware that brand names and availability vary internationally; always confirm product labelling when supplying cross‑border or export packs.

Guidelines For Proper Use

What Should Prescribers And Patients Do To Use Doxepin Safely?

Prescriber Checklist

Confirm the indication and prior treatment history before starting doxepin.

Review absolute contraindications including recent MAOI use and narrow‑angle glaucoma and document any cardiac history.

Obtain baseline vitals and consider ECG for patients with cardiac risk or the elderly.

Document hepatic and renal function before initiating and select starting dose according to condition and patient factors.

Titrate with weekly reviews early in treatment and plan duration according to indication, typically several months for depression and short‑term for insomnia unless specialist review advises otherwise.

Patient Counselling Essentials

Explain that antidepressant effects typically take one to three weeks and that sleep benefits at low dose may be noticed sooner.

Set expectations about sedation and anticholinergic effects and advise avoidance of alcohol and other CNS depressants.

Advise on missed doses and emphasise not to double doses; recommend gradual tapering when stopping to avoid rebound or discontinuation symptoms.

Instruct patients to seek urgent care for severe drowsiness, cardiac symptoms or seizures and to follow storage guidance for safety.

Delivery Across United Kingdom

Concluding Notes

Bottom Line: Doxepin Remains A Useful TCA With Distinctive Sedative Properties.

Use low‑dose doxepin for insomnia when antihistaminic effects are desired and consider standard antidepressant dosing for depression only after weighing risks and alternatives.

Monitor older patients and those with cardiac or hepatic comorbidity closely and always review interacting medicines.

If supply or brand questions arise, check product labelling for capsule strengths 10–100 mg, oral solution 10 mg/mL and Silenor 3 mg and 6 mg tablet packs before dispensing.

For urgent safety concerns, advise immediate medical assessment for severe drowsiness, cardiac symptoms or seizures.